Cell therapy weekly: Scribe Therapeutics and Sanofi collaborate to accelerate CRISPR-based cell therapies for cancer
This week: Industry-first benchtop cell analysis system unveiled by PerkinElmer, Scribe Therapeutics and Sanofi announce research collaboration for CRISPR-based cell therapies and Nucleus Biologics unveils new facility to expand manufacturing and cleanroom capacity.
The news highlights:
Industry-first benchtop cell analysis system unveiled by PerkinElmer
PerkinElmer Inc (MA, USA) have launched the Cellaca PLX system, a first-of-its-kind benchtop image cytometry platform designed to assess critical quality attributes of cell samples in a single automated workflow. The system includes image cytometer hardware, software, validated consumables and data reporting capabilities. This will enable simultaneous detection of multiple markers and allow researchers to perform immunophenotyping and viability assays in seconds.
Alan Fletcher, Senior Vice President of Life Sciences at PerkinElmer stated: “Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigor across their research and manufacturing processes. While the Cellaca PLX Image Cytometer platform is therapeutic area agnostic, it is expected to be especially beneficial for researchers working in CAR-T cell therapy who want to streamline their phenotyping of immune cells for downstream processes.”
Scribe Therapeutics and Sanofi announce research collaboration for CRISPR-based cell therapies
Scribe Therapeutics (CA, USA), a molecular engineering company focused on creating best-in-class in vivo therapies, and Sanofi (Paris, France) announced a strategic collaboration to accelerate breakthrough CRISPR-based cell therapies for oncology. Under the terms of the agreement, Sanofi will be granted non-exclusive rights to Scribe’s genome editing CasX-Editor technology to genetically modify novel natural killer cell therapies for cancer.
Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi stated: “At Sanofi, we are pushing the boundaries of science by developing a diverse range of next-generation therapies based on natural killer cells, which could have broad applications across solid tumors and blood cancers. This collaboration with Scribe complements our robust research efforts across the natural killer cell therapy spectrum and offers our scientists unique access to engineered CRISPR-based technologies as they strive to deliver off-the-shelf natural killer cell therapies and novel combination approaches that improve upon the first generation of cell therapies.”
Nucleus Biologics unveils new facility to expand manufacturing and cleanroom capacity
Nucleus Biologics (CA, USA) celebrated the unveiling of a new 19,884 square foot facility, increasing their total cell media manufacturing capacity to 2.5 million liters annually. The expansion includes state-of-the art cleanrooms built to ISO 7 specifications and a state-of-the-art WFI spec water system with ozone sanitization and real-time quality monitoring.
“This is an exciting time for Nucleus Biologics. We have seen rapid growth in both the cell and gene therapy industry and our business and are expanding manufacturing and cleanroom capacity to support our therapy customers to speed the time from discovery to cure. We are excited to share this achievement with the San Diego business community, local leaders, and our biotech and pharma customers.” said David Sheehan, Founder and CEO of Nucleus Biologics.
You might also like: